In 2016, approximately 1.9% (1 in 54) of US children 8 years of age were diagnosed with autism spectrum disorder (ASD),
1 and the prevalence has increased since then. That growth has spurred more expansive efforts to understand not only the prevalence of the disease but also its comorbidities and corresponding pharmacological treatments.
1,2